The stock of Hologic, Inc. (NASDAQ:HOLX) is a huge mover today! It is down 9.09% since March 1, 2016 and is uptrending. It has underperformed by 0.15% the S&P500.
The move comes after 7 months positive chart setup for the $10.90B company. It was reported on Oct, 4 by Barchart.com. We have $61.61 PT which if reached, will make NASDAQ:HOLX worth $6.21 billion more.
Analysts await Hologic, Inc. (NASDAQ:HOLX) to report earnings on November, 2. They expect $0.50 earnings per share, up 16.28% or $0.07 from last year’s $0.43 per share. HOLX’s profit will be $138.89 million for 19.62 P/E if the $0.50 EPS becomes a reality. After $0.51 actual earnings per share reported by Hologic, Inc. for the previous quarter, Wall Street now forecasts -1.96% negative EPS growth.
Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage
Out of 9 analysts covering Hologic (NASDAQ:HOLX), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Hologic has been the topic of 14 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Needham given on Thursday, April 28. The rating was upgraded by BTIG Research on Monday, October 26 to “Buy”. The company was initiated on Monday, October 26 by Gabelli. Barclays Capital upgraded Hologic, Inc. (NASDAQ:HOLX) on Wednesday, September 2 to “Equal Weight” rating. The stock of Hologic, Inc. (NASDAQ:HOLX) earned “Overweight” rating by Barclays Capital on Friday, September 23. The stock of Hologic, Inc. (NASDAQ:HOLX) earned “Underweight” rating by Barclays Capital on Thursday, July 30. The rating was maintained by Argus Research on Monday, August 3 with “Buy”. Stifel Nicolaus upgraded Hologic, Inc. (NASDAQ:HOLX) on Friday, December 11 to “Buy” rating. Craig Hallum downgraded the shares of HOLX in a report on Wednesday, October 21 to “Hold” rating. The firm has “Buy” rating given on Friday, September 18 by Jefferies.
According to Zacks Investment Research, “Hologic Inc. is a leading supplier of high quality, innovative and clinically valuable diagnostic systems and tests. The company develops, manufactures and markets X-ray bone densitometers and ultrasound bone analyzers that address a growing market for osteoporosis prevention and treatment — a key element of women’s health care. The systems are used by more leading medical schools, universities and osteoporosis opinion leaders than any other bone densitometer.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.02, from 1.04 in 2016Q1. The ratio turned negative, as 52 funds sold all Hologic, Inc. shares owned while 147 reduced positions. 53 funds bought stakes while 150 increased positions. They now own 258.39 million shares or 2.16% more from 252.92 million shares in 2016Q1.
Babson Cap Management Lc holds 0.08% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 87,000 shares. Nippon Life Comm has 0.03% invested in the company for 31,944 shares. Mitsubishi Ufj & accumulated 0.06% or 815,566 shares. Schwab Charles Inv Mgmt last reported 0.11% of its portfolio in the stock. The Maryland-based Rock Springs Capital Lp has invested 0.59% in Hologic, Inc. (NASDAQ:HOLX). Proshare Advsrs Ltd Limited Liability Company holds 0.03% or 62,786 shares in its portfolio. Cipher Cap L P accumulated 0.13% or 52,219 shares. Hanson And Doremus Invest Mgmt has 0.01% invested in the company for 400 shares. Moreover, Hightower Limited Co has 0% invested in Hologic, Inc. (NASDAQ:HOLX) for 7,606 shares. Marietta Invest Llc holds 0.28% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 22,694 shares. Profund Ltd Llc has 0.02% invested in the company for 10,081 shares. Verition Fund Management Limited Liability Co last reported 0.03% of its portfolio in the stock. Stevens Cap Mngmt Limited Partnership owns 179,174 shares or 0.25% of their US portfolio. Citigroup, a New York-based fund reported 8,648 shares. The New York-based Jpmorgan Chase & Com has invested 0.01% in Hologic, Inc. (NASDAQ:HOLX).
Insider Transactions: Since May 26, 2016, the stock had 0 insider purchases, and 7 selling transactions for $2.45 million net activity. $302,623 worth of shares were sold by LEAMING NANCY on Thursday, July 21. 10,022 Hologic, Inc. (NASDAQ:HOLX) shares with value of $339,089 were sold by Valenti Peter J. III. The insider Levy Lawrence M sold 17,794 shares worth $612,327. Oberton Karleen Marie sold $143,130 worth of stock. ULLIAN ELAINE also sold $233,430 worth of Hologic, Inc. (NASDAQ:HOLX) shares. $594,627 worth of Hologic, Inc. (NASDAQ:HOLX) was sold by CRAWFORD SALLY on Thursday, July 21.
More news for Hologic, Inc. (NASDAQ:HOLX) were recently published by: Prnewswire.com, which released: “Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior …” on October 03, 2016. Prnewswire.com‘s article titled: “FDA Expands Emergency Use Authorization for Hologic’s Aptima® Zika Virus Assay …” and published on September 08, 2016 is yet another important article.
HOLX Company Profile
Hologic, Inc., incorporated on January 18, 1990, is a developer, maker and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Firm operates through four divisions: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Firm sells and services its products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives. The Firm offers a range of diagnostic products, which are used to aid in the diagnosis of human diseases and screen donated human blood and plasma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.